Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large-cap value stocks. The market outlook is as uncertain as it gets. On January 18 ...

Truist Financial lifted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th.

Headlines,Eli Lilly Shares Experience a Decline,Key Analyst Activity and Ratings for LLY,What's Next for Eli Lilly's ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a global pharmaceutical firm, announced today the inauguration of the Lilly Seaport Innovation Center (LSC) in Boston's... Eli Lilly and ...

Eli Lilly's third quarter performance shows us the strength across key metrics, with especially impressive momentum in its core growth drivers. The company delivered total revenue of $11.44 ...

This page features the latest news about the Eli Lilly DRC stock. Eli Lilly : Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or ...